232 related articles for article (PubMed ID: 15809928)
21. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
22. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
López-Vélez R; Videla S; Márquez M; Boix V; Jiménez-Mejías ME; Górgolas M; Arribas JR; Salas A; Laguna F; Sust M; Cañavate C; Alvar J;
J Antimicrob Chemother; 2004 Mar; 53(3):540-3. PubMed ID: 14739148
[TBL] [Abstract][Full Text] [Related]
23. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation.
Singhal S; Ellis RW; Jones SG; Miller SJ; Fisher NC; Hastings JG; Mutimer DJ
Liver Transpl; 2000 Sep; 6(5):588-95. PubMed ID: 10980058
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of invasive zygomycosis infections in renal transplant recipients.
Forrest GN; Mankes K
Transpl Infect Dis; 2007 Jun; 9(2):161-4. PubMed ID: 17462005
[TBL] [Abstract][Full Text] [Related]
25. Controlled trials of amphotericin B lipid complex and other lipid-associated formulations.
Winston DJ; Schiller GJ
Clin Infect Dis; 2000 Jan; 30(1):236-7. PubMed ID: 10619780
[No Abstract] [Full Text] [Related]
26. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
[TBL] [Abstract][Full Text] [Related]
27. Use of amphotericin B lipid complex in elderly patients.
Hooshmand-Rad R; Chu A; Gotz V; Morris J; Batty S; Freifeld A
J Infect; 2005 May; 50(4):277-87. PubMed ID: 15845425
[TBL] [Abstract][Full Text] [Related]
28. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
[TBL] [Abstract][Full Text] [Related]
29. Severe and common side-effects of amphotericin B lipid complex (Abelcet).
Ringdén O; Jønsson V; Hansen M; Tollemar J; Jacobsen N
Bone Marrow Transplant; 1998 Oct; 22(7):733-4. PubMed ID: 9818706
[No Abstract] [Full Text] [Related]
30. Lipid-based amphotericin in pulmonary zygomycosis: safety and efficacy of high exposure in a renal allograft recipient.
Crompton JA; Alexander D; Somerville T; Shihab FS
Transpl Infect Dis; 2004 Dec; 6(4):183-7. PubMed ID: 15762937
[TBL] [Abstract][Full Text] [Related]
31. The experience is CLEAR.
Chandrasekar P
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248
[TBL] [Abstract][Full Text] [Related]
32. Amphotericin B lipid complex.
Rapp RP; Gubbins PO; Evans ME
Ann Pharmacother; 1997 Oct; 31(10):1174-86. PubMed ID: 9337444
[TBL] [Abstract][Full Text] [Related]
33. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B.
Barcia JP
Pharmacotherapy; 1998; 18(4):874-6. PubMed ID: 9692667
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections.
Linden P; Williams P; Chan KM
Clin Transplant; 2000 Aug; 14(4 Pt 1):329-39. PubMed ID: 10945204
[TBL] [Abstract][Full Text] [Related]
35. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.
Walsh TJ; Hiemenz JW; Seibel NL; Perfect JR; Horwith G; Lee L; Silber JL; DiNubile MJ; Reboli A; Bow E; Lister J; Anaissie EJ
Clin Infect Dis; 1998 Jun; 26(6):1383-96. PubMed ID: 9636868
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients.
Herbrecht R; Auvrignon A; Andrès E; Guillemain R; Suc A; Eyer D; Pailler C; Letscher-Bru V; Leverger G; Schaison G
Eur J Clin Microbiol Infect Dis; 2001 Feb; 20(2):77-82. PubMed ID: 11305476
[TBL] [Abstract][Full Text] [Related]
37. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
Ullmann AJ; Sanz MA; Tramarin A; Barnes RA; Wu W; Gerlach BA; Krobot KJ; Gerth WC;
Clin Infect Dis; 2006 Aug; 43(4):e29-38. PubMed ID: 16838223
[TBL] [Abstract][Full Text] [Related]
38. Side-effects of amphotericin B lipid complex (Abelcet) in the Scandinavian population.
Furebring M; Oberg G; Sjölin J
Bone Marrow Transplant; 2000 Feb; 25(3):341-3. PubMed ID: 10673711
[No Abstract] [Full Text] [Related]
39. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.
Miller CB; Waller EK; Klingemann HG; Dignani MC; Anaissie EJ; Cagnoni PJ; McSweeney P; Fleck PR; Fruchtman SM; McGuirk J; Chao NJ
Bone Marrow Transplant; 2004 Mar; 33(5):543-8. PubMed ID: 14730342
[TBL] [Abstract][Full Text] [Related]
40. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]